

JC10 Rec'd PCT/PTO 05 MAR 2002

FORM PTO-1390
(REV. 11-2000) modified

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

2645 USOP

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

10/070329

INTERNATIONAL APPLICATION NO.
PCT/JP00/06012

INTERNATIONAL FILING DATE
September 5, 2000

PRIORITY DATE CLAIMED
September 6, 1999

TITLE OF INVENTION

Process for the Preparation of 2, 3-Dihydroazepine Compounds

APPLICANT(S) FOR DO/EO/US

Tomomi IKEMOTO, Tatsuya ITO, Atsuko NISHIGUCHI, Kiminori TOMIMATSU

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Itemized Return Postcard
Certificate of Express Mailing
Copy of Forms PCT/IB/301, 304, 308 and 332

Express Mail Label No. EL 916492996 US

Date of Deposit March 5, 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.6)

10/070329

INTERNATIONAL APPLICATION NO
PCT/JP00/06012ATTORNEY'S DOCKET NUMBER
2645 USOP21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO..... \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS PTO USE ONLY**

\$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	30 - 20 =	10	x \$18.00	\$ 180.00
Independent claims	4 - 3 =	1	x \$84.00	\$ 84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$ 1,154.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$
SUBTOTAL =				\$ 1,154.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
TOTAL NATIONAL FEE =				\$ 1,154.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$
TOTAL FEES ENCLOSED =				\$ 1,154.00
				Amount to be refunded: \$
				charged: \$

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mark Chao, PhD, JD

Takeda Pharmaceuticals North America, Inc.

Suite 500, 475 Half Day Road

Lincolnshire, IL 60069 USA

(847)383-3372 fax (847)383-3481

SIGNATURE

Mark Chao, PhD, JD

NAME

37,293

REGISTRATION NUMBER

For Customer No. 23,115

PROCESS FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS

Technical Field

5 The present invention relates to a process for the preparation of 2,3-dihydrobenzazepine compounds as useful intermediates for compounds having CCR5 antagonistic activity.

Background Art

10 So far, for 2,3-dihydrobenzazepine derivatives, there has been described a process for synthesizing them by ring-closing diester derivatives of anthranilic acid by Dieckmann-type cyclization, followed by reduction and dehydration (U.S. Patent No. 4952573). However, this process has
15 a number of steps and requires complicated procedures.

Under these circumstances, there has been desired a simple and easy process for the preparation of 2,3-dihydrobenzazepine derivatives.


20 Disclosure of the Invention

The present inventors have extensively studied and, as a result, they have found a process for preparing 2,3-dihydrobenzazepine derivatives at low cost in a simple and easy manner using 4-(2-substituted-N-substituted anilino)-
25 butyric acids as intermediates. Based on such knowledge,


they have further studied and reached the completion of the present invention.

That is, the present invention relates to:


- (1) a process for the preparation of a compound of
5 the formula:



wherein each variable is as defined below, or a salt thereof, characterized in that a compound of the formula:



- 10 wherein X is a halogen atom; Y is an electron-withdrawing group; R⁶ and R⁷ are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group,
15 or an optionally substituted heterocyclic group; or R⁶ and R⁷ may form a ring, or a salt thereof, is allowed to react with a compound of the formula:




wherein R^1 is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or an optionally substituted sulfonyl group; R^2 , R^3 , R^4 , and R^5 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof;

(2) the preparation process as described above in (1), wherein Y is an optionally substituted acyl group;


(3) the preparation process as described above in (1), wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms;

(4) the preparation process as described above in (1), wherein R^1 is an optionally substituted hydrocarbon group;


(5) a process for the preparation of a compound of the formula:



wherein each variable is as defined below, or a salt thereof, characterized in that a compound of the formula:




5 wherein X is a halogen atom; Y is an electron-withdrawing group; and ring A is an optionally substituted benzene ring, or a salt thereof, is allowed to react with a compound of the formula:




10 wherein R¹ is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or an optionally substituted sulfonyl group; R², R³, R⁴, and R⁵ are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl

group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof;

- 5 (6) the preparation process as described above in (1), characterized in that a compound of the formula:




wherein each variable is as defined above in (1), or a salt thereof, is used, which is obtained by hydrolyzing a compound of the formula:




wherein each variable is as defined above in (1), or a salt thereof;

- (7) the preparation process as described above in (6),

characterized in that the compound of the formula:




wherein each variable is as defined above in (1), or a salt thereof, is subjected, without being isolated, to the reaction with the compound of the formula:



wherein each variable is as defined above in (1), or a salt thereof;

(8) a compound of the formula:



wherein Y is an electron-withdrawing group; R¹ is an optionally substituted hydrocarbon group, an optionally


substituted acyl group, or an optionally substituted sulfonyl group; R^2 , R^3 , R^4 , R^5 , R^6 , and R^7 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , R^2 and R^4 , or R^6 and R^7 may form a ring, or a salt thereof;

(9) the compound as described above in (8), wherein Y is an optionally substituted acyl group;

(10) the compound as described above in (8), wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms;

(11) the compound as described above in (8), wherein R^1 is an optionally substituted hydrocarbon group;

(12) a compound of the formula:



wherein Y is an electron-withdrawing group; ring A is an optionally substituted benzene ring; R^1 is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or an optionally substituted sulfonyl group; R^2 ,


R^3 , R^4 , and R^5 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof;

(13) the compound as described above in (12), wherein Y is an optionally substituted acyl group;


(14) the compound as described above in (12), wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms;

(15) the compound as described above in (12), wherein R^1 is an optionally substituted hydrocarbon group;

(16) a process for the preparation of a compound of the formula:



wherein R^8 is an optionally substituted hydrocarbon group and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein each variable is as defined above in (1), or a salt thereof, which is obtained by the preparation process as described above in (1), is subjected to esterification;

(17) the preparation process as described above in (16), wherein Y is an optionally substituted acyl group;

(18) the preparation process as described above in (16), wherein R², R³, R⁴, and R⁵ are hydrogen atoms;


(19) the preparation process as described above in (16), wherein R¹ is an optionally substituted hydrocarbon group;

(20) a process for the preparation of a compound of the formula:




wherein R⁸ is an optionally substituted hydrocarbon group

and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein each variable is as defined above in (5), or a salt thereof, which is obtained by the preparation process as described above in (5), is subjected to esterification;

(21) a process for the preparation of a compound of the formula:



wherein R⁹ is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein Y^a is a group of formula -COR⁹ wherein R⁹ is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined above in (16), or a salt thereof, which is obtained by the preparation process as described above in (16), is subjected to ring-closing reaction;

(22) the preparation process as described above in (21), wherein R⁹ is a hydrogen atom;

(23) the preparation process as described above in (21), wherein R², R³, R⁴, and R⁵ are hydrogen atoms;


(24) the process as described above in (21), wherein R¹ is an optionally substituted hydrocarbon group;

(25) the preparation process as described above in (21), characterized in that a compound of the formula:




wherein Y^a is a group of formula -COR⁹ wherein R⁹ is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined above in (16), or a salt thereof, which is obtained by the preparation process as described above in (16), is subjected, without being isolated, to ring-closing reaction;

(26) a process for the preparation of a compound of the formula:



wherein R⁹ is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined above in (20), or a salt thereof, which is obtained by the preparation process as described above in (20), is subjected to ring-closing reaction;

(27) the preparation process as described above in (26), wherein R^9 is a hydrogen atom;

(28) the preparation process as described above in (26), wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms;

(29) the preparation process as described above in (26), wherein R^1 is an optionally substituted hydrocarbon group;

(30) the preparation process as described above in (26), characterized in that a compound of the formula:



wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined above in (20), or a salt thereof, which is obtained by the preparation process as described above in (20), is subjected, without being isolated, to ring-closing reaction; and the like.

The "electron-withdrawing group" as used herein may include: (i) an optionally esterified or amidated carboxyl group; (ii) a group of formula $-(CO)R^{20}$ wherein R^{20} is hydrogen or an optionally substituted hydrocarbon group; (iii) a nitrile group; (iv) a nitro group; (v) a group of formula $-(SO_m)R^{10}$ wherein m is 1 or 2, and R^{10} is an optionally substituted hydrocarbon group; (vi) a group of formula $-PR^{11}R^{12}$ wherein R^{11} and R^{12} are independently an optionally substituted hydrocarbon group; (vii) a group of formula $-(PO)(OR^{13})(OR^{14})$ wherein R^{13} and R^{14} are independently hydrogen or an optionally substituted hydrocarbon group; (viii) an optionally substituted aryl group; (ix) an optionally substituted alkenyl group; (x) a halogen atom (e.g., fluo-

rine, chlorine, bromine, iodine); and (xi) a nitroso group. Preferred are an optionally esterified or amidated carboxyl group, a group of formula $-(CO)R^9$, a nitrile group, a nitro group, a group of formula $-(SO_m)R^{10}$, a group of formula $-PR^{11}R^{12}$, and a group of formula $(PO)(OR^{13})(OR^{14})$. More preferred are an optionally esterified carboxyl group (e.g., C_{1-4} alkyl-esterified carboxyl group such as methoxycarbonyl, ethoxycarbonyl, and t-butoxycarbonyl).

The "esterified carboxyl group" in the "optionally esterified or amidated carboxyl group" described above in (i) may include a group of formula $-(CO)OR^{15}$ wherein R^{15} is hydrogen or an optionally substituted hydrocarbon group. The "amidated carboxyl group" may include a group of formula $-(CO)NR^{16}R^{17}$ wherein R^{16} and R^{17} are independently hydrogen or an optionally substituted hydrocarbon group, or R^{16} and R^{17} may be combined together with an adjacent nitrogen atom to form 5- to 7-membered (preferably, 5- to 6-membered) cyclic amino (e.g., tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, imidazole).

In addition, in the formula described above in (vi) or (vii), R^{11} and R^{12} or R^{13} and R^{14} may be combined together to form lower (C_{2-6}) alkylene (e.g., dimethylene, trimethylene, tetramethylene), lower (C_{2-6}) alkenylene (e.g., $-CH_2-CH=CH-$, $-CH_2-CH_2-CH=CH-$, $-CH_2-CH=CH-CH_2-$), and lower (C_{4-6}) alka-dienylene (e.g., $-CH=CH-CH=CH-$), preferably lower (C_{1-6})

alkylene, and more preferably lower (C_{2-4}) alkylene. These divalent groups may have a substituent(s). The substituent may include a hydroxyl group, halogen, C_{1-4} alkyl, and C_{1-4} alkoxy.

5 The "aryl group" in the optionally substituted aryl group described above in (viii) may include C_{6-14} aryl such as phenyl and naphthyl, preferably C_{6-10} aryl, and more preferably phenyl. The aryl group may have 1 to 3 substituents which are the same substituents as those optionally
10 carried by the "optionally substituted hydrocarbon group" as described below.

 The "alkenyl group" in the optionally substituted alkenyl group described above in (ix) may include alkenyl of 2 to 10 carbon atoms, such as vinyl, allyl, crotyl,
15 2-pentenyl, and 3-hexenyl, preferably lower (C_{2-6}) alkenyl, and more preferably vinyl. The alkenyl group may have 1 to 3 substituents which are the same substituents as those optionally carried by the "optionally substituted hydrocarbon group" as described below.

20 The "hydrocarbon group" in the "optionally substituted hydrocarbon group" as used herein may include:

 (1) alkyl (e.g., C_{1-10} alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl,
25 and decyl, preferably lower (C_{1-6}) alkyl);

(2) cycloalkyl (e.g., C_{3-7} cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl);

(3) alkenyl (e.g., alkenyl of 2 to 10 carbon atoms, such as vinyl, allyl, crotyl, 2-pentenyl, and 3-hexenyl, preferably lower (C_{2-6}) alkenyl);

(4) cycloalkenyl (e.g., cycloalkenyl of 3 to 7 carbon atoms, such as 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, and 2-cyclohexenylmethyl);

(5) alkynyl (e.g., alkynyl of 2 to 10 carbon atoms, such as ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-pentylnyl, and 3-hexynyl, preferably lower (C_{2-6}) alkynyl);

(6) aryl (e.g., C_{6-14} aryl such as phenyl and naphthyl, preferably C_{6-10} aryl, and more preferably phenyl);

(7) aralkyl (e.g., phenyl- C_{1-4} alkyl (e.g., benzyl and phenethyl)); and the like.

Among all these groups, preferred is alkyl, more preferred is C_{1-4} alkyl such as methyl or ethyl, and in particular, preferably used is methyl.

The hydrocarbon group may have a substituent(s). The substituent may include halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, a hydroxyl group, an optionally substituted thiol group (e.g., thiol, C_{1-4} alkylthio), an optionally substituted amino group (e.g., amino, mono- C_{1-4} alkylamino, di- C_{1-4} alkylamino, 5- to 6-membered

cyclic amino such as tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, and imidazole), an optionally esterified or amidated carboxyl group (e.g., carboxyl, C₁₋₄ alkoxy carbonyl, carbamoyl, mono-C₁₋₄ alkyl-

5 carbamoyl, di-C₁₋₄ alkylcarbamoyl), C₁₋₄ alkyl optionally substituted with a halogen atom or C₁₋₄ alkoxy (e.g., trifluoromethyl, methyl, ethyl), C₁₋₄ alkoxy optionally substituted with a halogen atom or C₁₋₄ alkoxy (e.g., methoxy, ethoxy, trifluoromethoxy, and trifluoroethoxy), formyl, C₂₋₄

10 alkanoyl (e.g., acetyl, propionyl), C₁₋₄ alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), and C₁₋₄ alkylsulfinyl (e.g., methanesulfinyl, ethanesulfinyl). The number of substituents may preferably be 1 to 3.

In the above formulas, R¹ and R², R¹ and R⁴, R² and R³, R⁴ and R⁵, or R² and R⁴ may be combined together with an

15 adjacent carbon atom or with adjacent carbon and nitrogen atoms to form a ring by forming lower (C₂₋₆) alkylene (e.g., dimethylene, trimethylene, tetramethylene), lower (C₂₋₆) alkenylene (e.g., -CH₂-CH=CH-, -CH₂-CH₂-CH=CH-, -CH₂-CH=CH-

20 CH₂), and lower (C₄₋₆) alkadienylene (e.g., -CH=CH-CH=CH-), preferably lower (C₁₋₆) alkylene, and more preferably lower (C₂₋₄) alkylene. In addition, these divalent groups may have a substituent(s). The substituent may include a hydroxyl group, halogen, C₁₋₄ alkyl, and C₁₋₄ alkoxy.

25 The "halogen atom" represented by X, R², R³, R⁴, R⁵, R⁶,

or R⁷ in the above formulas may include fluorine, chlorine, bromine, and iodine.

The "optionally substituted amino group" represented by R², R³, R⁴, R⁵, R⁶, or R⁷ in the above formulas may include the amino group optionally substituted with the "optionally substituted hydrocarbon group" as described above. The number of substituents may be any of 0 to 2 and, when two substituents are present, these two substituents may be the same or different. Alternatively, two substituents may be combined together with an adjacent nitrogen atom to form 5- to 7-membered (preferably, 5- to 6-membered) cyclic amino (e.g., tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, imidazole).

The "optionally substituted hydroxyl group" represented by R², R³, R⁴, R⁵, R⁶, or R⁷ in the above formulas may include a hydroxyl group optionally substituted with the "optionally substituted hydrocarbon group" as described above.

The "optionally substituted thiol group" represented by R², R³, R⁴, R⁵, R⁶, or R⁷ in the above formulas may include a thiol group optionally substituted with the "optionally substituted hydrocarbon group" as described above.

The "heterocyclic ring" in the "optionally substituted heterocyclic group" represented by R², R³, R⁴, R⁵, R⁶, or R⁷

in the above formulas may include a 5- to 7-membered aromatic heterocyclic ring, and a saturated or unsaturated non-aromatic heterocyclic ring (aliphatic heterocyclic ring) containing at least one (preferably 1 to 4, more preferably 1 or 2) of one to three kinds (preferably, one to two kinds) of heteroatoms selected from an oxygen atom, a sulfur atom, a nitrogen atom, and the like.

The "aromatic heterocyclic ring" may include 5- to 6-membered aromatic monocyclic heterocyclic rings (e.g., furan, thiophene, pyrrole, oxazole, isooxazole, thiazole, isothiazole, imidazole, pyrazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, furazane, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazine). The "non-aromatic heterocyclic ring" may include 5- to 7-membered (preferably, 5- to 6-membered) saturated or unsaturated (preferably, saturated) non-aromatic heterocyclic rings (aliphatic heterocyclic rings) such as pyrrolidine, tetrahydrofuran, thiolane, piperidine, tetrahydropyran, morpholine, thiomorpholine, piperazine, and pyran); and 5- to 6-membered non-aromatic heterocyclic rings in which some or all of the double bonds in the above aromatic monocyclic heterocyclic rings have been saturated. As the heterocyclic rings, preferred are 5- to 6-membered aromatic rings. Further, furan, thiophene, pyrrole, and

pyridine (preferably, 6-membered ring) are preferred.

The substituents optionally carried by the heterocyclic rings may include the same substituents as those optionally carried by the "optionally substituted hydrocarbon group" as described above. The number of substituents may be 1 to 3.

In the above formulas, the Y may preferably be an optionally substituted acyl group. In particular, preferred is a group of the formula $-(CO)R^{20}$ wherein R^{20} is hydrogen or an optionally substituted hydrocarbon group. The R^1 may preferably be an optionally substituted hydrocarbon group. The R^2 , R^3 , R^4 , or R^5 may preferably be a hydrogen atom or an optionally substituted hydrocarbon group, more preferably a hydrogen atom. The R^9 may preferably be a hydrogen atom. The R^6 or R^7 may preferably be combined together to form an optionally substituted benzene ring.

The substituents optionally carried by the "optionally substituted benzene ring" as used herein may include the same substituents as those optionally carried by the "optionally substituted hydrocarbon group" as described above; the above "optionally substituted aryl group" which may be bonded through a spacer (e.g., a divalent group of 1 to 4 atoms forming a straight chain moiety) (preferably, the above "optionally substituted aryl group" which is

directly bonded). In particular, it may preferably be an electron-donating group. The number of substituents may be 1 to 4.

The "spacer" may include $-(CH_2)_a-$ [wherein a is an integer of 1 to 4 (preferably, integer of 1 to 2)], $-(CH_2)_b-X'-$ [wherein b is an integer of 0 to 3 (preferably 0 or 1) and X' is an optionally substituted imino group (e.g., an imino group optionally substituted with lower (C_{1-6}) lower alkyl, lower (C_{3-7}) cycloalkyl, formyl, lower (C_{2-7}) lower alkanoyl, lower (C_{1-6}) lower alkoxy-carbonyl, or the like), a carbonyl group, an oxygen atom or an optionally oxidized sulfur atom (e.g., $-S(O)_n-$ wherein n is an integer of 0 to 2)], $-CH=CH-$, $-C\equiv C-$, $-CO-NH-$, and $-SO_2-NH-$ (preferably $-(CH_2)_b-X'-$, more preferably $-CH_2-O-$). These groups may be bonded with the "optionally substituted benzene ring" through either their right or left bond. They may preferably be bonded with the "optionally substituted benzene ring" through their right bond.

The ring formed by combining R^6 and R^7 may include 5- to 7-membered (preferably, 5- to 6-membered) unsaturated alicyclic hydrocarbons such as C_{5-7} cycloalkene (e.g., 1-cyclopentene, 2-cyclopentene, 3-cyclopentene, 2-cyclohexene, 3-cyclohexene) and C_{5-6} cycloalkadiene (e.g., 2,4-cyclopentadiene, 2,4-cyclohexadiene, 2,4-cyclohexadiene); 6-membered aromatic hydrocarbons such as benzene; 5- to 7-membered

aromatic heterocyclic rings and unsaturated non-aromatic heterocyclic rings (aliphatic heterocyclic rings), which contain at least one (preferably 1 to 4, more preferably 1 or 2) of one to three kinds (preferably, one or two kinds) of heteroatoms selected from an oxygen atom, a sulfur atom, a nitrogen atom, and the like.

The "aromatic heterocyclic rings" may include 5- to 6-membered aromatic monocyclic heterocyclic rings (e.g., furan, thiophene, pyrrole, oxazole, isooxazole, thiazole, isothiazole, imidazole, pyrazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, pyridine, pyridazine, pyrimidine, pyrazine). The "non-aromatic heterocyclic rings" may include 5- to 6-membered non-aromatic heterocyclic rings in which some of the double bonds in the above aromatic monocyclic heterocyclic rings are saturated.

The ring formed by combining R^6 and R^7 may preferably be a 5- to 6-membered aromatic ring. Further, preferred are benzene, furan, thiophene, pyrrole, and pyridine (preferably, 6-membered rings). In particular, benzene is preferred.

The ring formed by combining R^6 and R^7 may have a substituent(s). The substituents may include the same substituents as those optionally carried by the benzene ring in the "optionally substituted benzene ring" as described above. One to three of the same or different

substituents may be attached to any replaceable position.

The leaving group used herein may include a halogen atom (e.g., fluorine, chlorine, bromine, iodine) and a group of formula $-O(SO_m)R$ wherein m is 1 or 2, and R is an optionally substituted hydrocarbon group (preferably, optionally halogenated C_{1-4} alkyl, and more preferably trifluoromethyl). Among all these groups, preferred is a halogen atom, and particularly preferred is a fluorine atom.

The "optionally substituted acyl group" represented by R^1 in the above formulas may include a group of formula $-(CO)R'$ wherein R' is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group. The "optionally substituted heterocyclic group" represented by R' may include the same as the "optionally substituted heterocyclic group" represented by R^2 , R^3 , R^4 , R^5 , R^6 , or R^7 .

The "substituted sulfonyl group" represented by R^1 in the above formulas may include a group of formula $-(SO_2)R''$ wherein R'' is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group. The "optionally substituted heterocyclic group" represented by R'' may include the same as the "optionally substituted heterocyclic group" represented by R^2 , R^3 , R^4 , R^5 , R^6 , or R^7 .

Depending upon the kinds of substituents as described above, when compounds having these substituents are basic


compounds, they can be converted into salts by the use of an acid according to the ordinary method. The acid may be any one, so long as it does not adversely affect the reaction. Examples thereof may include inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, and sulfamic acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, tartaric acid, citric acid, fumaric acid, maleic acid, succinic acid, malic acid, p-toluenesulfonic acid, methanesulfonic acid, and benzenesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid. When the resulting compounds are salts, they may be converted into free bases according to the ordinary method.

On the other hand, depending upon the kinds of substituents as described above, when compounds having these substituents are acidic compounds, they can be converted into salts by the use of a base according to the ordinary method. The salt with a base may be a salt with any base, so long as it does not adversely affect the reaction. Examples thereof may include salts with inorganic bases, salts with organic bases, and salts with basic amino acids. Preferred examples of the salts with inorganic bases may include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; as well as aluminum salts and


ammonium salts. Preferred examples of the salts with organic bases may include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, and N,N'-di-
 5 benzylethylenediamine. Preferred examples of the salts with basic amino acids may include salts with arginine, lysine, and ornithine. When the resulting compounds are salts, they may be converted into free acids according to the ordinary method.

10 The reaction described above in (1) is carried out, for example, under the following reaction conditions.

A compound of the formula:




wherein each variable is as defined above, or a salt there-
 15 of, is reacted with a compound of the formula:



wherein each variable is as defined above, or a salt there-

of, to give a compound of the formula:



wherein each variable is as defined above, or a salt thereof.

- 5 The reaction described above in (1) is preferably carried out in the presence of a base. The base may include metal hydrides (e.g., alkali metal hydrides such as sodium hydride and potassium hydride), metal hydrocarbons (e.g., compounds each having a chemical bond in which C₁₋₄
- 10 alkyl is directly bonded with an alkali metal, such as n-butyl lithium), alcoholates (e.g., compounds in which the hydrogen of a hydroxyl group in a C₁₋₄ alcohol is replaced with an alkali metal, such as NaOMe, NaOEt, t-BuONa, and t-BuOK), alkali metal hydroxides (e.g., NaOH, KOH), basic
- 15 carbonates (e.g., carbonates with alkali metal salts such as sodium salts, potassium salts, and cesium salts, or with alkaline earth metal salts such as calcium salts and magnesium salts), basic bicarbonates (e.g., hydrogencarbonates with alkali metal salts such as sodium salts and potassium
- 20 salts), organic bases (e.g., trimethylamine, triethylamine,


diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, and 1,8-diazabicyclo[5.4.0]-7-undecene). Among all these bases, preferably used are

5 basic carbonates (e.g., carbonates with alkali metal salts such as sodium salts, potassium salts, and cesium salts, or with alkaline earth metal salts such as calcium salts and magnesium salts).

The amount of base used in the reaction described


10 above in (1) is about 0.1 to 100 equivalents, preferably about 0.5 to 5 equivalents.

Relative to the compound of the formula:



wherein each variable is as defined above, or a salt thereof,

15 of, the compound of the formula:



wherein each variable is as defined above, or a salt thereof


of, is used at about 0.1 to 100 equivalents, preferably about 0.5 to 5 equivalents.

As the reaction solvent, used are halogen solvents (e.g., methylene chloride, dichloroethane, chloroform),
5 aliphatic hydrocarbons (e.g., n-hexane), aromatic hydrocarbons (e.g., benzene, toluene), ethers (e.g., tetrahydrofuran (THF), diethyl ether, isopropyl ether (IPE)), polar solvents (e.g., water, acetonitrile, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC)),
10 and protonic solvents (e.g., alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol, and 2-methoxyethanol). In the reaction, a suitable mixed solvent may be used. Among all these solvents, preferably used are polar solvents (preferably, water-containing DMSO and water-
15 containing DMAC).


The reaction temperature is usually about 0°C to 200°C, preferably about 50°C to 150°C. The reaction time is usually about 0.5 to 100 hours, preferably about 1 to 50 hours.

The reaction described above in (5) is carried out,
20 for example, by the following step.


The compound of the formula:



wherein each variable is as defined above, or a salt thereof, is reacted with the compound of the formula:



wherein each variable is as defined above, or a salt thereof, to give a compound of the formula:




wherein each variable is as defined above, or a salt thereof.


The reaction described above in (5) is carried out under the same reaction conditions as those for the reaction described above in (1).

The reaction described above in (6) is carried out, for example, under the following reaction conditions:


The compound of the formula:



wherein each variable is as defined above, or a salt thereof, is hydrolyzed to give a compound of the formula:



- 5 wherein each variable is as defined above, or a salt thereof, and the resulting compound or a salt thereof is subjected to the reaction described above in (1) to give a compound of the formula:




wherein each variable is as defined above, or a salt thereof. In this reaction, the intermediate may or may not be isolated; however, two steps may preferably be carried out continuously without isolating the intermediate.


5 The above hydrolysis can be carried out according to the method known per se and, for example, can be carried out by hydrolysis with an acid or an alkali. As the acid, for example, hydrochloric acid, sulfuric acid, or hydrobromic acid is used. As the alkali, lithium hydroxide, 10 potassium hydroxide, sodium hydroxide, calcium hydroxide, or barium hydroxide is used.

The reaction described above in (16) is carried out, for example, under the following reaction conditions.

The compound of the formula:



15 wherein each variable is as defined above, or a salt thereof, which is obtained by the reaction described above in (1), is subjected to esterification to give a compound of the formula:




wherein each variable is as defined above, or a salt thereof.

The esterification is a reaction for converting free acids into esters by the means known per se. For example, esters can be prepared by reacting free acids or their reactive derivatives with alcohols (R^8-OH) corresponding to substituent R^8 , or reacting free acids or their salts with halogenated alkyl compounds ($X-R^5$ wherein X is a halogen atom) corresponding to substituent R^8 .


The reaction described above in (20) is carried out, for example, by the following step.

The compound of the formula:



wherein each variable is as defined above, or a salt thereof.

of, which is obtained by the process described above in (5), is subjected to esterification to give a compound of the formula:




5 wherein each variable is as defined above, or a salt thereof.

The reaction described above in (20) is carried out, for example, under the same reaction conditions as those for the reaction described above in (16).


10 The reaction described above in (21) is carried out, for example, under the following conditions.

The compound of the formula:



15 wherein each variable is as defined above, or a salt thereof, which is obtained by the reaction described above in

(16), is subjected to ring-closing reaction to give a compound of the formula:



wherein each variable is as defined above, or a salt thereof. In this reaction, the intermediate obtained by the reaction described above in (16) may or may not be isolated; however, two steps may preferably be carried out continuously without isolating the intermediate.

The reaction described above in (21) may preferably be carried out in the presence of a base. The base may include metal hydrides (e.g., alkali metal hydrides such as sodium hydride and potassium hydride), metal hydrocarbons (e.g., compounds each having a chemical bond in which C₁₋₄ alkyl is directly bonded with an alkali metal, such as n-butyl lithium), alcoholates (e.g., compounds in which the hydrogen of a hydroxy group in a C₁₋₄ alcohol is replaced with an alkali metal, such as NaOMe, NaOEt, t-BuONa, and t-BuOK), alkali metal hydroxides (e.g., NaOH, KOH), basic carbonates (e.g., carbonates with alkali metal salts such

as sodium salts, potassium salts, and cesium salts, or with alkaline earth metal salts such as calcium salts and magnesium salts), basic bicarbonates (e.g., bicarbonates with alkali metal salts such as sodium salts and potassium salts), organic bases (e.g., trimethylamine, triethylamine, diisopropylethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]-7-undecene). Among all these bases, preferably used are alcoholates (e.g., compounds in which the hydrogen of a hydroxy group in a C₁₋₄ alcohol is replaced with an alkali metal, such as NaOMe, NaOEt, t-BuONa, and t-BuOk).

The amount of base used in the reaction described above in (21) is about 0.1 to 100 equivalents, preferably about 0.5 to 5 equivalents.


As the reaction solvent, used are halogen solvents (e.g., methylene chloride, dichloroethane, chloroform), aliphatic hydrocarbons (e.g., n-hexane), aromatic hydrocarbons (e.g., benzene, toluene), ethers (e.g., tetrahydrofuran (THF), diethyl ether, isopropyl ether (IPE)), polar solvents (e.g., water, acetonitrile, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), DMAC), protonic solvents (e.g., alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol, and 2-methoxyethanol), carbonic acid diesters (e.g., carbonic acid di-C₁₋₄ alkyl esters such as

dimethyl carbonate and diethyl carbonate), formic acid esters (e.g., formic acid C₁₋₄ alkyl esters), and oxalic acid diesters (e.g., oxalic acid di-C₁₋₄ alkyl ester). In the reaction, a suitable mixed solvent may be used. Among all these solvents, preferably used are solvents containing carbonic acid diesters.


The reaction temperature is usually about -20°C to 200°C, preferably about 10°C to 100°C. The reaction time is usually about 0.1 to 100 hours, preferably about 0.5 to 50 hours.

The reaction described above in (26) is carried out, for example, by the following step.

The compound of the formula:




wherein each variable is as defined above, or a salt thereof, which is obtained by the reaction described above in (20), is subjected to ring-closing reaction to give a compound of the formula:



wherein each variable is as defined above, or a salt thereof.


The reaction described above in (26) is carried out, for example, under the same reaction conditions as those for the reaction described above in (21).

The compound of the formula:



wherein Y is an electron-withdrawing group; R¹ is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or a substituted sulfonyl group; R², R³, R⁴, R⁵, R⁶, and R⁷ are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally sub-


stituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , R^2 and R^4 , or R^6 and R^7 may form a ring, or a salt thereof, which is
 5 obtained by the reaction described above in (1); and the compound of the formula:




wherein Y is an electron-withdrawing group; ring A is an optionally substituted benzene ring; R^1 is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or a substituted sulfonyl group; R^2 , R^3 , R^4 , and R^5 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group,
 10 an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof, are novel compounds and useful as intermediates
 15 for synthesizing anilide derivatives described, for example, in WO99/32100, WO99/32468, and Japanese Patent Application
 20

No. 11-170345, by their being subjected to esterification and ring-closing reaction according to the reactions described above in (16) and (21), respectively, followed by the optional hydrolysis of the resulting esters, and then
 5 condensation with aniline derivatives according to the method known per se.

In addition, the compound of the formula:




wherein each variable is as defined above, or a salt thereof, which is obtained by the reaction described above in
 10 (26), can be converted into a free acid, a salt thereof, or a reactive derivative thereof, and then subjected to condensation with the compound of the formula:



15 wherein R²³ and R²⁴ are independently an optionally substituted hydrocarbon group or an optionally substituted

heterocyclic group, or a salt thereof (well-known condensation described, for example, in WO99/32100 or WO99/32468) to give a compound of the formula:



5 wherein each variable is as defined above, or a salt thereof.

In the above formulas, the "optionally substituted heterocyclic group" represented by R²³ or R²⁴ may include the same groups as the "optionally substituted heterocyclic group" represented by R², R³, R⁴, R⁵, R⁶, or R⁷.

In the above formulas, the R²³ may preferably be an optionally substituted straight chain hydrocarbon group (e.g., optionally substituted alkyl, optionally substituted alkenyl), more preferably an optionally substituted lower C₁₋₆ alkyl group, and particularly preferred is a methyl group.

The R²⁴ may preferably be an optionally substituted

alicyclic hydrocarbon group (e.g., optionally substituted cycloalkyl or cycloalkenyl; preferably, an optionally substituted lower C₃₋₈ cycloalkyl group; more preferably cyclohexyl) or an optionally substituted alicyclic heterocyclic group (preferably, an optionally substituted saturated alicyclic heterocyclic group (preferably, 6-membered cyclic group); more preferably, optionally substituted tetrahydropyranyl, optionally substituted tetrahydrothiopyranyl, or optionally substituted piperidyl; particularly preferably, tetrahydropyranyl).

The Best Mode for Carrying Out the Invention

The present invention will be further illustrated by reference to the following Reference Examples and Examples; however, these are only illustrative and do not limit the present invention in any way.

Examples

Example 1

Synthesis of 4-(4-bromo-2-formyl-N-methylanilino)-butyric acid

To a suspension of 5-bromo-2-fluorobenzaldehyde (20.3 g) and 4-methylaminobutyric acid hydrochloride (18.4 g) in DMSO/water (100 ml/100 ml) was slowly add sodium carbonate (25.4 g), followed by stirring at 105°C to 110°C for 3.5 hours. The mixture was cooled to 50°C to 60°C, at

which temperature 6N hydrochloric acid was added dropwise to adjust the pH to 3. The mixture was extracted with ethyl acetate (200 ml + 100 ml), and the organic layer was washed with a saturated aqueous sodium chloride solution (40 ml x 2) and water (40ml). The organic layer was concentrated, and the concentrate was then dissolved in IPE (50 ml), to which n-hexane (50 ml) was added dropwise. The precipitates were filtered out and washed with IPE/n-hexane (16 ml/4 ml). The filter cake was dried under reduced pressure at room temperature for 4 hours to give 4-(4-bromo-2-formyl-N-methylanilino)butyric acid (25.9 g, 86% yield) as yellow crystals.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.95 (2H, tt, $J = 6.5, 7.4$ Hz), 2.38 (2H, t, $J = 6.5$ Hz), 2.88 (3H, s), 3.17 (2H, t, $J = 7.4$ Hz), 7.01 (1H, d, $J = 8.7$ Hz), 7.55 (1H, dd, $J = 8.7, 2.5$ Hz), 7.87 (1H, d, $J = 2.5$ Hz), 10.16 (1H, s).

Example 2

Synthesis of 4-(4-bromo-2-formyl-N-methylanilino)-butyric acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-methylanilino)butyric acid (1.00 g) and potassium carbonate (0.51 g) in DMF (5ml) was added ethyl iodide (0.26 ml), followed by stirring at room temperature for 24 hours. To the reaction mixture was added water, followed by extraction with ethyl acetate. The organic layer was washed with

a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated. The concentrate was purified on a silica gel column (n-hexane/-ethyl acetate (4/1)) to give 4-(4-bromo-2-formyl-N-methylanilino)butyric acid ethyl ester (0.84g, 77% yield) as an oil.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.24 (3H, t, $J = 7.1$ Hz), 1.93 (2H, tt, $J = 7.1, 7.7$ Hz), 2.30 (2H, t, $J = 7.1$ Hz), 2.88 (3H, s), 3.15 (2H, t, $J = 7.7$ Hz), 4.12 (2H, q, $J = 7.1$ Hz), 7.01 (1H, d, $J = 8.8$ Hz), 7.55 (1H, dd, $J = 8.8, 2.5$ Hz), 7.87 (1H, d, $J = 2.5$ Hz), 10.17 (1H, s).

Example 3

Synthesis of 4-(4-bromo-2-formyl-N-methylanilino)-butyric acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-methylanilino)butyric acid (1.00 g) and potassium carbonate (0.55 g) in DMF (5 ml) was added ethyl bromide (0.30 ml), followed by stirring at room temperature for 10 hours. To the reaction mixture was added water, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated. The concentrate was purified on a silica gel column (n-hexane/-ethyl acetate (4/1)) to give 4-(4-bromo-2-formyl-N-methylanilino)butyric acid ethyl ester (0.98 g, 90% yield) as an

oil.

Example 4

Synthesis of 4-(4-bromo-2-formyl-N-methylanilino)-
butyric acid methyl ester

5 To a suspension of 4-(4-bromo-2-formyl-N-methyl-
anilino)butyric acid (2.00 g) and potassium carbonate
(1.01 g) in DMF (10 ml) was added ethyl iodide (0.46 ml),
followed by stirring at room temperature for 2 hours. To
the reaction mixture was added water, followed by extrac-
10 tion with ethyl acetate. The organic layer was washed with
a saturated aqueous sodium chloride solution, dried over
anhydrous sodium sulfate, and then concentrated. The
concentrate was purified on a silica gel column (n-hexane/-
ethyl acetate (4/1)) to give 4-(4-bromo-2-formyl-N-methyl-
15 anilino)butyric acid methyl ester (1.76 g, 84% yield) as an
oil.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.94 (2H, tt, $J = 7.2, 7.5$
Hz), 2.32 (2H, t, $J = 7.2$ Hz), 2.87 (3H, s), 3.15 (2H, t, J
= 7.5 Hz), 3.66 (3H, s), 7.01 (1H, d, $J = 8.8$ Hz), 7.55 (1H,
20 dd, $J = 8.8, 2.5$ Hz), 7.87 (1H, d, $J = 2.5$ Hz), 10.17 (1H,
s).

Example 5

Synthesis of 7-bromo-1-methyl-2,3-dihydro-1-benzaze-
pine-4-carboxylic acid ethyl ester

25 To a solution of 4-(4-bromo-2-formyl-N-methylanilino)-

butyric acid ethyl ester (0.97 g) in diethyl carbonate (20 ml) was added a 20% ethanolic sodium ethylate solution (1.21 g), followed by stirring at room temperature for 4 hours. The mixture was neutralized with 1N hydrochloric acid, followed by extraction with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated to give 7-bromo-1-methyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester (0.83 g, 90% yield) as yellow crystals.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.34 (3H, t, $J = 7.0$ Hz), 2.84 (2H, t, $J = 4.5$ Hz), 3.01 (3H, s), 3.22 (2H, t, $J = 4.5$ Hz), 4.25 (2H, q, $J = 7.0$ Hz), 6.65 (1H, d, $J = 8.9$ Hz), 7.26 (1H, dd, $J = 8.9, 2.4$ Hz), 7.42 (1H, d, $J = 2.4$ Hz), 7.56 (1H, s).

Example 6

Synthesis of 7-bromo-1-methyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-methylanilino)butyric acid (1.00 g) and potassium carbonate (0.55 g) in DMF (3 ml) was added ethyl bromide (0.30 ml), followed by stirring at room temperature overnight. Then added were diethyl carbonate (6 ml) and a 20% ethanolic sodium ethylate solution (2.72 g), followed by stirring at 50°C for 1 hour. The mixture was neutralized with 2N hydrochloric acid, followed by extraction with ethyl

acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. The concentrate was purified on a silica gel column (n-hexane/ethyl acetate (4/1)) to give 7-bromo-1-methyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester (0.86 g, 83% yield) as yellow crystals.

Example 7

Synthesis of 7-bromo-1-methyl-2,3-dihydro-1-benzazepine-4-carboxylic acid methyl ester

To a solution of 4-(4-bromo-2-formyl-N-methylanilino)-butyric acid methyl ester (0.50 g) in dimethyl carbonate (10 ml) was added a 28% methanolic sodium methylate solution (0.37 g), followed by stirring at room temperature for 5.5 hours. The mixture was neutralized with 1N hydrochloric acid, followed by extraction with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, and then concentrated. To the concentrate was added IPE (5ml), followed by stirring at room temperature for 0.5 hour. The crystals were filtered out, washed with IPE (5mL), and dried under reduced pressure at room temperature for 4 hours to give 7-bromo-1-methyl-2,3-dihydro-1-benzazepine-4-carboxylic acid methyl ester (0.39 g, 83% yield) as yellow crystals.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 2.85 (2H, t, $J = 5.1$ Hz), 3.00 (3H, s), 3.23 (2H, t, $J = 5.1$ Hz), 3.80 (3H, s), 6.67

(1H, d, $J = 8.8$ Hz), 7.26 (1H, dd, $J = 8.8, 2.4$ Hz), 7.42 (1H, d, $J = 2.4$ Hz), 7.56 (1H, s).

Example 8

Synthesis of 4-(4-bromo-2-formyl-N-butylanilino)-
5 butyric acid

A solution of 1-butyl-2-pyrrolidone (3.75 ml) in concentrated hydrochloric acid (7 ml) was refluxed for 24 hours. The pH was adjusted to 6 with 6N aqueous sodium hydroxide. Further added were water (8 ml), sodium carbonate (10.60 g), and a solution of 5-bromo-2-fluorobenzaldehyde (5.10 g) in DMSO (25 ml), followed by stirring at 105°C to 110°C for 5.5 hours. The mixture was cooled to 50°C to 60°C, at which temperature 6N hydrochloric acid was added dropwise to adjust the pH to 6. The aqueous layer
10 was washed with IPE, and the organic layer was extracted with 2N aqueous sodium hydroxide (25 ml). The aqueous layer was adjusted to pH = 1 and extracted with ethyl acetate/THF (4/1, 25 ml \times 3), after which the organic layer was washed with a saturated aqueous sodium chloride solution (25 ml \times 2). The organic layer was concentrated, and the concentrate was then purified on a silica gel column (n-hexane/ethyl acetate (2/1, then 1/1)) to give 4-(4-bromo-2-formyl-N-butylanilino)butyric acid (7.20 g, 84%
15 yield) as an oil.

25 $^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 0.85 (3H, t, $J = 7.3$ Hz),

1.23-1.28 (2H, m), 1.43-1.48 (2H, m), 1.86 (2H, tt, $J = 7.1$,
7.3 Hz), 2.34 (2H, t, $J = 7.1$ Hz), 3.11 (2H, t, $J = 7.6$ Hz),
3.19 (2H, t, $J = 7.3$ Hz), 7.06 (1H, d, $J = 8.7$ Hz), 7.57
(1H, dd, $J = 8.7$, 2.5 Hz), 7.90 (1H, d, $J = 2.5$ Hz), 10.22
5 (1H, s).

Example 9

Synthesis of 7-bromo-1-butyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-butylani-
10 lino)butyric acid (1.00 g) and potassium carbonate (0.49 g)
in DMF (3 ml) was added ethyl bromide (0.26 ml), followed by
stirring at room temperature for 24 hours. Then added were
diethyl carbonate (6 ml) and a 20% ethanolic sodium ethyl-
ate solution (2.39 g), followed by stirring at 50°C for
15 1.5 hours. The mixture was neutralized with 2N hydro-
chloric acid, followed by extraction with ethyl acetate.
The organic layer was washed with water and concentrated.
The concentrate was then purified on a silica gel column
(n-hexane/ethyl acetate (10/1)) to give 7-bromo-1-butyl-
20 2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester
(0.83 g, 81% yield) as an oil.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 0.96 (3H, t, $J = 7.3$ Hz),
1.28-1.37 (5H, m), 1.60-1.66 (2H, m), 2.79 (2H, t, $J = 4.4$
Hz), 3.19-3.29 (4H, m), 4.25 (2H, q, $J = 7.2$ Hz), 6.68 (1H,
25 d, $J = 8.9$ Hz), 7.23 (1H, dd, $J = 8.9$, 2.4 Hz), 7.41 (1H, d,

$J = 2.4 \text{ Hz}$), 7.55 (1H, s).

Reference Example 1

Synthesis of 1-propyl-2-pyrrolidone

A suspension of 2-pyrrolidone (40.0 g), propionalde-
5 hyde (109.0 g), anhydrous sodium sulfate (106.0 g), and 20%
Pd-C (wet, 10.0 g) in ethyl acetate (470 ml) was stirred
under an atmosphere of 4 MPa hydrogen at 100°C for 4 hours.
After cooling to room temperature, insolubles were filtered
and washed with ethyl acetate. The mother liquid was con-
10 centrated, and the concentrate was then distilled under
reduced pressure (72°C to 77°C/5 mmHg) to give 1-propyl-2-
pyrrolidone (56.2 g, 94% yield) as a colorless oil.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 0.90 (3H, t, 7.4 Hz), 1.49-
1.61 (2H, m), 1.97-2.05 (2H, m), 2.40 (2H, t, $J = 8.3 \text{ Hz}$),
15 3.25 (2H, t, $J = 7.6 \text{ Hz}$), 3.39 (2H, t, $J = 7.1 \text{ Hz}$).

Reference Example 2

Synthesis of 1-propyl-2-pyrrolidone

A suspension of potassium hydroxide (36.3g) and tetra-
butylammonium bromide (9.5 g) in toluene (250 ml) was re-
20 fluxed using Dean Stark apparatus. Under the same condi-
tions, a solution of 2-pyrrolidone (50.0 g) and propane
bromide (94.0 g) in toluene (50 ml) was added dropwise over
2 hours, followed by stirring for 1.5 hours. After cooling
to room temperature, insolubles were filtered. The fil-
25 trate was washed with a saturated aqueous sodium chloride

solution/water (100 ml/100 ml), dried over anhydrous sodium sulfate, and then concentrated. The concentrate was then distilled under reduced pressure to give 1-propyl-2-pyrrolidone (41.5 g, 56% yield) as a colorless oil.

5 Reference Example 3

Synthesis of 4-propylaminobutyric acid

To a solution of 1-propyl-2-pyrrolidone (11.9 g) in water (150 ml) was added barium hydroxide octahydrate (53.25 g), followed by heating under reflux for 24 hours. After cooling, dry ice was added to precipitate insolubles. After filtration, insolubles were precipitated by the addition of sulfuric acid to the mother liquid. The insolubles were filtered out, and the solvent was then distilled out to give 4-propylaminobutyric acid (9.8 g, 72% yield) as a white solid.

$^1\text{H-NMR}$ (D_2O , δ , 300 MHz): 0.69 (3H, t, $J = 7.4$ Hz), 1.47-1.40 (2H, m), 1.67-1.60 (2H, m), 2.01 (2H, t, $J = 7.2$ Hz), 2.82-2.69 (4H, m).

Example 10

20 Synthesis of 4-(4-bromo-2-formyl-N-propylanilino)-butyric acid

To a solution of 4-propylaminobutyric acid (5.8 g) in DMSO/water (40 ml/40 ml) were added 5-bromo-2-fluorobenzaldehyde (4.06 g) and sodium carbonate (6.36 g), followed by heating to reflux for 6 hours. After cooling, water (40ml)

was added, and the mixture was washed with 50ml of IPE. The organic layer was extracted with 2N aqueous sodium hydroxide (30 ml). The combined aqueous layer was adjusted to around pH = 3, and extracted with ethyl acetate/THF (50 ml/50 ml). The aqueous layer was extracted with ethyl acetate (50 ml x 2). The combined organic layer was washed with a saturated aqueous sodium chloride solution, and the solvent was then distilled out to give 4-(4-bromo-2-formyl-N-propylanilino)butyric acid (5.4 g, 82% yield) as an oil.

¹H-NMR (CDCl₃, δ, 300 MHz): 0.83 (3H, t, J = 7.4 Hz), 1.54-1.47 (2H, m), 1.88-1.81 (2H, m), 2.34 (2H, t, J = 7.2 Hz), 3.11-3.06 (2H, m), 3.22-3.18 (2H, m), 7.07 (1H, d, J = 8.7 Hz), 7.57 (1H, dd, J = 8.7, 2.5 Hz), 7.90 (1H, d, J = 2.5 Hz), 10.22 (1H, s).

Example 11

Synthesis of 4-(4-bromo-2-formyl-N-propylanilino)-butyric acid

A solution of 1-propyl-2-pyrrolidone (2.54 g) in a 4N aqueous sodium hydroxide solution (10ml) was stirred for 8 hours, while heating under reflux. After cooling, concentrated hydrochloric acid (3.3 ml) was added. Then added were a solution of 5-bromo-2-fluorobenzaldehyde (2.03 g) in DMSO (20 ml) and sodium carbonate (4.24 g), followed by heating under reflux for 7 hours. After cooling, water (10 ml) and THF (10 ml) were added, and the mixture was

adjusted to pH = 3.5 with 6N hydrochloric acid. The mixture was extracted with ethyl acetate (20 ml) and then further extracted with ethyl acetate/THF (20 ml/10 ml). The combined organic layer was washed with a saturated aqueous sodium chloride solution/water (10 ml/10 ml × 2) and then concentrated. The concentrate was purified on a silica gel column (n-hexane/ethyl acetate (4/1, then 2/1)) to give 4-(4-bromo-2-formyl-N-propylanilino)butyric acid (2.90 g, 88% yield) as an oil.

Example 12

Synthesis of 4-(4-bromo-2-formyl-N-propylanilino)-butyric acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-propylanilino)butyric acid (5.4 g) and potassium carbonate (2.74 g) in DMF (25 ml) was added ethyl bromide (1.5 ml), followed by stirring at room temperature for 24 hours. Water (30 ml) was added, followed by extraction with ethyl acetate (50 ml). Further, the aqueous layer was extracted with ethyl acetate (25 ml × 2). The combined organic layer was washed with a saturated aqueous sodium chloride solution and then concentrated. The concentrate was purified on a silica gel column (n-hexane, then n-hexane/ethyl acetate (20/1, then 15/1, then 10/1)) to give 4-(4-bromo-2-formyl-N-propylanilino)butyric acid ethyl ester (3.74 g, 64% yield) as an oil.

¹H-NMR (CDCl₃, δ, 300 MHz): 0.83 (3H, t, J = 7.4 Hz),
1.23 (3H, t, J = 7.1 Hz), 1.52-1.49 (2H, m), 1.84-1.79 (2H,
m), 2.27 (2H, t, J = 7.2 Hz), 3.11-3.06 (2H, m), 3.20-3.16
(2H, m), 4.10 (2H, q, J = 7.1 Hz), 7.07 (1H, d, J = 8.7 Hz),
5 7.56 (1H, dd, J = 8.7, 2.6 Hz), 7.90 (1H, d, J = 2.6 Hz),
10.22 (1H, s).

Example 13

Synthesis of 7-bromo-1-propyl-2,3-dihydro-1-benzaze-
pine-4-carboxylic acid ethyl ester

10 To a solution of 4-(4-bromo-2-formyl-N-propylanilino)-
butyric acid ethyl ester (3.00 g) in diethyl carbonate
(60 ml) was added dropwise a 20% ethanolic sodium ethoxide
solution (3.44 g), followed by stirring at room temperature
for 4 hours. Under ice-cooling, the mixture was adjusted
15 to pH = 2 with 1N hydrochloric acid (10 ml), and the layers
were separated. Further, the aqueous layer was extracted
with ethyl acetate (30 ml). The combined organic layer was
washed with a saturated aqueous sodium chloride solution
and then concentrated. The concentrate was purified on a
20 silica gel column (n-hexane, then n-hexane/ethyl acetate
(10/1, then 7/1)) to give 7-bromo-1-propyl-2,3-dihydro-1-
benzazepine-4-carboxylic acid methyl ester (2.34 g, 82%
yield) as an oil.

¹H-NMR (CDCl₃, δ, 300 MHz): 0.94 (3H, t, J = 7.4 Hz),
25 1.34 (3H, t, J = 7.1 Hz), 1.72-1.64 (2H, m), 2.81-2.78 (2H,

m), 3.25-3.19 (4H, m), 4.25 (2H, q, $J = 7.1$ Hz), 6.68 (1H, d, $J = 8.9$ Hz), 7.22 (1H, dd, $J = 8.9, 2.4$ Hz), 7.41 (1H, d, $J = 2.4$ Hz), 7.55 (1H, s).

Example 14

5 Synthesis of 7-bromo-1-propyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

To a suspension of 4-(4-bromo-2-formyl-N-propylanilino)butyric acid (4.00 g) and potassium carbonate (2.02 g) in DMF (12 ml) was added ethyl bromide (1.1 ml), followed
10 by stirring at room temperature for 6 hours. Then added was diethyl carbonate (24 ml), to which a 20% ethanolic sodium ethoxide solution (10.00 g) was added dropwise, followed by stirring at 60°C for 1 hour. Under ice-cooling, the mixture was adjusted to pH = 2 with 1N hydrochloric
15 acid (50 ml), and the layers were separated. Further, the aqueous layer was extracted with ethyl acetate (50 ml). The combined organic layer was washed with a saturated aqueous sodium chloride solution and then concentrated. The concentrate was purified on a silica gel column
20 (n-hexane, then n-hexane/ethyl acetate (10/1, then 7/1)) to give 7-bromo-1-propyl-2,3-dihydro-1-benzazepiene-4-carboxylic acid ethyl ester (3.41 g, 83% yield) as an oil.

Example 15

25 Synthesis of 4-[4-(4-butoxyethoxyphenyl)-2-formyl-N-propylanilino]butyric acid

Under an argon atmosphere, magnesium (0.076 g) was suspended in THF (6.75 ml), to which a solution of 4-butoxyethoxybromobenzene (0.83 g) in THF (2.25 ml) was added dropwise, while heating under reflux, followed by stirring at the same temperature for 2 hours. After cooling, a solution of trimethoxyborane (0.32 g) in THF (2.25 ml) was added dropwise at -10°C or below. After stirring at the same temperature for 0.5 hour, the mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, and to the resulting residue were added toluene (6 ml), ethanol (2 ml), palladium acetate (3.4 mg), and triphenylphosphine (16 mg), followed by stirring at room temperature for 0.5 hour. 4-(4-Bromo-2-formyl-N-propylanilino)butyric acid (0.5 g) and an aqueous solution of potassium carbonate (1.1 g) in water (2 ml) were added. While heating under reflux, the mixture was stirred for 3.5 hours. After cooling, 2N hydrochloric acid (11 ml) was added dropwise, and the pH was adjusted to 3 using a 2N aqueous sodium hydroxide solution. After the layers were separated, toluene (10 ml) was added to the aqueous layer, followed by extraction. The organic layers were combined, washed with a 20% aqueous sodium chloride solution (7.5 ml \times 2), and concentrated under reduced pressure. The resulting residue was purified on a silica gel column (n-hexane/ethyl acetate = 2 : 1) to give 4-(4-

butoxyethoxyphenyl-2-formyl-N-propylanilino)butyric acid
(0.5 g, 75.5% yield).

¹H-NMR (CDCl₃, δ, 300 MHz): 0.84 (3H, t, J = 7.4 Hz),
0.93 (3H, t, J = 7.3 Hz), 1.3-1.45 (2H, m), 1.50-1.68 (4H,
5 m), 1.80-1.95 (2H, m), 2.30-2.38 (2H, m), 3.09-3.14 (2H, m),
3.53-3.58 (2H, m), 3.55 (2H, t, J = 6.7 Hz), 3.78-3.83 (2H,
m), 4.13-4.18 (2H, m), 6.99 (2H, d, J = 8.7 Hz), 7.22 (1H,
d, J = 8.5 Hz), 7.51 (2H, d, J = 8.7 Hz), 7.69 (1H, dd, J =
8.5, 2.4 Hz), 7.99 (1H, d, J = 2.4 Hz), 10.37 (1H, s).

10 Reference Example 4

Synthesis of 5-(4-butoxyethoxyphenyl)-2-fluorobenz-
aldehyde

Under an argon atmosphere, magnesium (4.9 g) was sus-
pended in THF (270 ml), to which a solution of 4-butoxy-
15 ethoxybromobenzene (53.8 g) in THF (90 ml) was added drop-
wise, while heating under reflux, followed by stirring at
the same temperature for 2 hours. After cooling, a solu-
tion of trimethoxyborane (20.5 g) in THF (90 ml) was added
dropwise at -10°C. After stirring at the same temperature
20 for 0.5 hour, the mixture was stirred at room temperature
for 1 hour. Palladium acetate (221 mg) and triphenylphos-
phine (1.03 g) were added, and the mixture was stirred at
room temperature for 0.5 hour. 5-Bromo-2-fluorobenzalde-
hyde (20 g) and an aqueous solution of potassium carbonate
25 (71.5 g) in water (85 ml) were added. The mixture was

stirred for 2.5 hours, while heating under reflux. After cooling, 2N hydrochloric acid (450 ml) was added dropwise, and the layers were separated. To the aqueous layer was added toluene (450ml), followed by extraction. The organic layers were combined, and washed with 2N hydrochloric acid (300 ml), a 2N aqueous sodium hydroxide solution (300 ml x 2), and a 20% aqueous sodium chloride solution (300 ml x 3). To the organic layer was added active carbon (1 g), followed by stirring at room temperature for 20 hours. The active carbon was filtered out, followed by concentration under reduced pressure. The resulting residue was purified on a silica gel column (n-hexane/ethyl acetate = 5 : 1) to give 5-(4-butoxyethoxyphenyl)-2-fluorobenzaldehyde (28.2 g, 90.5% yield).

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 0.93 (3H, t, $J = 7.3$ Hz), 1.26-1.46 (2H, m), 1.56-1.66 (2H, m), 3.55 (2H, t, $J = 6.6$ Hz), 3.78-3.81 (2H, m), 4.12-4.18 (2H, m), 7.00 (2H, dd, $J = 6.6, 2.1$ Hz), 7.21 (1H, dd, $J = 9.9, 8.7$ Hz), 7.49 (2H, dd, $J = 6.6, 2.1$ Hz), 7.47-7.79 (1H, m), 8.02 (1H, dd, $J = 6.5, 2.5$ Hz), 10.40 (1H, s).

Example 16

Synthesis of 4-[4-(4-butoxyethoxyphenyl)-2-formyl-N-propylanilino]butyric acid

1-Propyl-2-pyrrolidone (0.8 g) was dissolved in a 2N aqueous sodium hydroxide solution (6.3 ml), followed by

stirring for 8 hours, while heating under reflux. After cooling, 12N hydrochloric acid (1 ml) was added for neutralization, and a solution of sodium carbonate (1.34 g) and 5-(4-butoxyethoxyphenyl)-2-fluorobenzaldehyde (1 g) in dimethyl sulfoxide (7.3 ml) was added. The mixture was stirred for 49 hours, while heating under reflux. After cooling, 2N hydrochloric acid (12 ml) was added, and the pH was adjusted to 3 using a 2N aqueous sodium hydroxide solution. The mixture was extracted with toluene (10 ml \times 2). The organic layer was washed with a 20% aqueous sodium chloride solution (10 ml \times 2), dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The resulting residue was purified on a silica gel column (n-hexane/ethyl acetate = 2 : 1) to give 4-(4-butoxyethoxyphenyl-2-formyl-N-propylanilino)butyric acid (0.2 g, 15% yield).

Example 17

4-(2-Formyl-N-methylanilino)butyric acid

Using 2-fluorobenzaldehyde, the reaction was carried out in the same manner as described in Example 1 to give 4-(2-formyl-N-methylanilino)butyric acid in 78% yield as a brown oil.

EI-MS m/z: 221 (M^+)

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.92 (2H, tt, $J = 7.2, 7.3$ Hz), 2.36 (2H, t, $J = 7.2$ Hz), 2.85 (3H, s), 3.15 (2H, t, J

= 7.3 Hz), 7.06-7.10 (2H, m), 7.43-7.49 (1H, m), 7.75 (1H, dd, $J = 7.7, 1.7$ Hz), 10.23 (1H, s).

IR (neat, cm^{-1}): 2960, 1708, 1683, 1596.

Example 18

5 4-(2-Formyl-4-nitro-N-methylanilino)butyric acid

Using 2-chloro-5-nitrobenzaldehyde, the reaction was carried out in the same manner as described in Example 1 to give 4-(2-formyl-4-nitro-N-methylanilino)butyric acid in 92% yield as yellow crystals.

10 m.p.: 100°C to 101°C.

Anal. for $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_5$:

Calcd.: C, 54.13; H, 5.30; N, 10.52;

Found.: C, 54.06; H, 5.31; N, 10.43.

^1H -NMR (CDCl_3 , δ , 300 MHz): 2.01 (2H, tt, $J = 6.9, 7.5$ Hz), 2.39 (2H, t, $J = 6.9$ Hz), 3.04 (3H, s), 3.46 (2H, t, $J = 7.5$ Hz), 7.2 (1H, d, $J = 9.3$ Hz), 8.19 (1H, dd, $J = 9.3, 2.3$ Hz), 8.57 (1H, d, $J = 2.3$ Hz), 9.95 (1H, s).

IR (KBr, cm^{-1}): 1693, 1598, 1315, 1257, 1228.

Example 19

20 1-Methyl-2,3-dihydro-1-benzaldehyde-4-carboxylic acid ethyl ester

Using 4-(2-formyl-N-methylanilino)butyric acid, the reaction was carried out in the same manner as described in Example 6 to give 1-methyl-2,3-dihydro-1-benzaldehyde-4-carboxylic acid ethyl ester in 74% yield as a yellow oil.

EI-MS m/z : 231 (M^+).

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.31 (3H, t, $J = 7.1$ Hz),
2.81 (2H, t, $J = 4.3$ Hz), 3.00 (3H, s), 3.22 (2H, t, $J =$
4.9 Hz), 4.22 (2H, q, $J = 7.1$ Hz), 6.75-6.80 (2H, m), 7.16-
7.30 (2H, m), 7.66 (1H, s).

IR (neat, cm^{-1}): 1702, 1689, 1498, 1255, 1186.

Example 20

1-Methyl-7-nitro-2,3-dihydro-1-benzazepine-4-carbox-
ylic acid ethyl ester

Using 4-(2-formyl-4-nitro-N-methylanilino)butyric acid,
the reaction was carried out in the same manner as de-
scribed in Example 6 to give 1-methyl-7-nitro-2,3-dihydro-
1-benzaldehyde-4-carboxylic acid ethyl ester in yield 72%
as yellow crystals.

m.p.: 113°C to 114°C .

Anal. for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_4$:

Calcd.: C, 60.86; H, 5.84; N, 10.14;

Found.: C, 60.50; H, 5.84; N, 10.03.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.32 (3H, t, $J = 7.1$ Hz),
2.86 (2H, t, $J = 4.5$ Hz), 3.13 (3H, s), 3.35 (2H, t, $J =$
4.9 Hz), 4.24 (2H, q, $J = 7.1$ Hz), 6.71 (1H, d, $J = 9.3$ Hz),
7.62 (1H, s), 8.01 (1H, dd, $J = 9.3, 2.7$ Hz), 8.22 (1H, d,
 $J = 2.7$ Hz).

IR (KBr, cm^{-1}): 1697, 1596, 1565, 1321, 1299, 1257,
1187.

Example 21

7-[4-(Butoxyethoxyphenyl)]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

Using 4-[4-(butoxyethoxyphenyl)-2-formyl-N-propylanilino]butyric acid, the reaction was carried out in the same manner as described in Example 14 to give 7-[4-(butoxyethoxyphenyl)]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester in 76% yield as a yellow oil.

EI-MS m/z : 451 (M^+).

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 0.93-1.00 (6H, m), 1.34-1.45 (5H, m), 1.57-1.65 (2H, m), 1.72-1.78 (2H, m), 2.82-2.86 (2H, m), 3.28-3.35 (4H, m), 3.57 (2H, t, $J = 6.6$ Hz), 3.82 (2H, t, $J = 4.7$ Hz), 4.18 (2H, t, $J = 5.2$ Hz), 4.29 (2H, q, $J = 7.1$ Hz), 6.88 (1H, d, $J = 8.6$ Hz), 7.00 (2H, d, $J = 8.6$ Hz), 7.41 (1H, dd, $J = 8.6, 2.0$ Hz), 7.51 (2H, d, $J = 8.6$ Hz), 7.53 (1H, d, $J = 2.0$ Hz), 7.77 (1H, s).

IR (neat, cm^{-1}): 1697, 1500, 1241, 1178.

Example 22

4-(4-Bromo-2-formyl-N-isopropylanilino)butyric acid

Using N-isopropyl-2-pyrrolidone, the reaction was carried out in the same manner as described in Example 11 to give 4-(4-bromo-2-formyl-N-isopropylanilino)butyric acid in 22% yield as yellow crystals.

m.p.: 96°C to 98°C .

Anal. for $\text{C}_{14}\text{H}_{18}\text{NO}_3\text{Br}$:

Calcd.: C, 51.23; H, 5.53; N, 4.27; Br, 24.35;

Found.: C, 51.01; H, 5.56; N, 4.22; Br, 24.61.

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.11 (6H, d, $J = 6.6$ Hz),
1.71-1.77 (2H, m), 2.35 (2H, t, $J = 7.1$ Hz), 3.15 (2H, t, J
5 = 6.7 Hz), 3.27-3.33 (1H, m), 7.11 (1H, d, $J = 8.6$ Hz),
7.60 (1H, dd, $J = 8.6, 2.6$ Hz), 7.95 (1H, d, $J = 2.6$ Hz),
10.21 (1H, s).

IR (KBr, cm^{-1}): 2969, 1700, 1675, 1473, 1213, 1178.

Example 23

10 4-(4-Bromo-2-formyl-N-cyclohexylanilino)butyric acid

Using N-cyclohexyl-2-pyrrolidone, the reaction was
carried out in the same manner as described in Example 11
to give 4-(4-bromo-2-formyl-N-cyclohexylanilino)butyric
acid in 3% yield as a brown oil.

15 EI-MS m/z : 367 (M^+).

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.08-1.38 (5H, m), 1.52-
1.85 (7H, m), 2.33 (2H, t, $J = 7.0$ Hz), 2.74-2.88 (1H, m),
3.20 (2H, t, $J = 7.3$ Hz), 7.12 (1H, d, $J = 8.7$ Hz), 7.57
(1H, dd, $J = 8.7, 2.5$ Hz), 7.93 (1H, d, $J = 2.5$ Hz), 10.21
20 (1H, s).

IR (neat, cm^{-1}): 2931, 2856, 1706, 1681, 1471.

Example 24

4-(4-Bromo-2-formyl-N-allylanilino)butyric acid

Using N-allyl-2-pyrrolidone, the reaction was carried
25 out in the same manner as described in Example 11 to give

4-(4-bromo-2-formyl-N-allylanilino)butyric acid in 50%
yield as a brown oil.

El-MS m/z : 325 (M^+).

$^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.85 (2H, tt, $J = 7.1, 7.4$
5 Hz), 2.35 (2H, t, $J = 7.1$ Hz), 3.19 (2H, t, $J = 7.4$ Hz),
3.71 (2H, d, $J = 6.3$ Hz), 5.17-5.23 (2H, m), 5.73-5.84 (1H,
m), 7.05 (1H, d, $J = 8.7$ Hz), 7.58 (1H, dd, $J = 8.7, 2.5$
Hz), 7.90 (1H, d, $J = 2.5$ Hz), 10.24 (1H, s).

IR (neat, cm^{-1}): 2962, 1708, 1681, 1261, 1178.

10 Example 25

4-[4-Bromo-2-formyl-N-(2-methoxybenzyl)anilino]butyric
acid

To a solution of 2-methoxybenzaldehyde (3.0 g) in
methanol (42 ml) were added 4-aminobutyric acid (2.3 g) and
15 1N sodium hydroxide (22 ml). A Kolben was purged with
argon, to which 20% Pd-C (wet, 0.3 g) was added. The
Kolben was purged with hydrogen, followed by stirring at
room temperature for 4 hours. The Pd-C was filtered out,
and the mixture was then washed with methanol. To the
20 filtrate was added 6N hydrochloric acid (3.7 ml), followed
by concentration to dryness. Then added were DMSO/water
(29 ml/15 ml), 5-bromo-4-fluorobenzaldehyde (2.2 g), and
sodium carbonate (4.7 g), followed by stirring for 5 hours,
while heating under reflux. After cooling to room tem-
25 perature, the pH was adjusted to about 3.5 with 6N hydro-

chloric acid. After extraction with ethyl acetate, the organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated. The concentrate was purified on a silica gel column (n-hexane/ethyl acetate = 2/1), and the effective fractions were concentrated to give 4-[4-bromo-2-formyl-N-(2-methoxybenzyl)anilino]butyric acid (3.5 g, 90% content, 70% yield) as a brown oil.

FAB-MS m/z : 428 ($M^+ + Na$).

1H -NMR ($CDCl_3$, δ , 300 MHz): 1.95 (2H, tt, $J = 7.2, 6.9$ Hz), 2.35 (2H, t, $J = 7.2$ Hz), 3.16 (2H, t, $J = 6.9$ Hz), 3.66 (3H, s), 4.28 (2H, s), 6.79-6.86 (2H, m), 6.98-7.06 (2H, m), 7.25 (1H, d, $J = 8.7$ Hz), 7.53 (1H, dd, $J = 8.7, 2.5$ Hz), 7.88 (1H, d, $J = 2.5$ Hz), 10.23 (1H, s).

IR (neat, cm^{-1}): 1706, 1671, 1475, 1245.

Example 26

7-Bromo-1-isopropyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

Using 4-(4-bromo-2-formyl-N-isopropylanilino)butyric acid, the reaction was carried out in the same manner as described in Example 14 to give 7-bromo-1-isopropyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester in 73% yield as a brown oil.

EI-MS m/z : 337 (M^+).

1H -NMR ($CDCl_3$, δ , 300 MHz): 1.23 (6H, d, $J = 6.6$ Hz),

1.34 (3H, t, $J = 7.1$ Hz), 2.75-2.78 (2H, m), 3.12-3.15 (2H, m), 3.94-4.02 (1H, m), 4.25 (2H, q, $J = 7.1$ Hz), 6.70 (1H, d, $J = 8.9$ Hz), 7.24 (1H, dd, $J = 8.9, 2.4$ Hz), 7.42 (1H, d, $J = 2.4$ Hz), 7.54 (1H, s).

5 IR (neat, cm^{-1}): 1698, 1492, 1251, 1213, 1184.

Example 27

7-Bromo-1-cyclohexyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

10 Using 4-(4-bromo-2-formyl-N-cyclohexylanilino)butyric acid, the reaction was carried out in the same manner as described in Example 14 to give 7-bromo-1-cyclohexyl-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester in 44% yield as yellow crystals.

15 $^1\text{H-NMR}$ (CDCl_3 , δ , 300 MHz): 1.33 (3H, t, $J = 7.1$ Hz), 1.14-2.04 (10H, m), 2.73 (2H, m), 3.19 (2H, m), 3.49 (1H, m), 4.24 (2H, q, $J = 7.1$ Hz), 6.67 (1H, d, $J = 8.9$ Hz), 7.21 (1H, dd, $J = 8.9, 2.3$ Hz), 7.41 (1H, d, $J = 2.3$ Hz), 7.53 (1H, s).

IR (KBr , cm^{-1}): 2929, 1695, 1488, 1253, 1240.

20 Example 28

1-Allyl-7-bromo-2,3-dihydro-1-benzazepine-4-carboxylic acid methyl ester

25 Using 4-(4-bromo-2-formyl-N-allylanilino)butyric acid, the reaction was carried out in the same manner as described in Example 14 to give 1-allyl-7-bromo-2,3-

dihydro-1-benzazepine-4-carboxylic acid methyl ester in 50% yield as yellow crystals.

m.p.: 51°C to 53°C.

Anal. for $C_{15}H_{16}NO_2Br$:

5 Calcd.: C, 55.92; H, 5.01; N, 4.35; Br, 24.80;

Found.: C, 55.84; H, 4.94; N, 4.19; Br, 24.80.

1H -NMR ($CDCl_3$, δ , 300 MHz): 2.78 (2H, t, $J = 5.0$ Hz), 3.21 (2H, d, $J = 5.0$ Hz), 3.80 (3H, s), 3.90 (2H, m), 5.21 (1H, d, $J = 15.3$ Hz), 5.25 (1H, d, $J = 10.2$ Hz), 5.58 (1H, 10 m), 6.68 (1H, d, $J = 8.8$ Hz), 7.22 (1H, dd, $J = 8.8, 2.4$ Hz), 7.43 (1H, d, $J = 2.4$ Hz), 7.58 (1H, s).

IR (KBr, cm^{-1}): 1698, 1496, 1265, 1238, 1176.

Example 29

15 7-Bromo-1-(2-methoxybenzyl)-2,3-dihydro-1-benzazepine-4-carboxylic acid ethyl ester

Using 4-[4-bromo-2-formyl-N-(2-methoxybenzyl)anilino]-butyric acid, the reaction was carried out in the same manner as described in Example 14 to give 7-bromo-1-(2-methoxybenzyl)-2,3-dihydro-1-benzazepine-4-carboxylic acid 20 ethyl ester in 90% yield as a yellow oil.

EI-MS m/z : 415 (M^+).

1H -NMR ($CDCl_3$, δ , 300 MHz): 1.30 (3H, t, $J = 7.1$ Hz), 2.77 (2H, m), 3.26 (2H, m), 3.84 (3H, s), 4.23 (2H, q, $J = 7.1$ Hz), 4.47 (2H, s), 6.57 (1H, d, $J = 8.8$ Hz), 6.86-6.91 25 (2H, m), 7.03 (1H, d, $J = 6.2$ Hz), 7.13 (1H, dd, $J = 8.8,$

2.4 Hz), 7.26 (1H, d, $J = 6.2$ Hz), 7.43 (1H, d, $J = 2.4$ Hz), 7.60 (1H, s).


IR (neat, cm^{-1}): 1697, 1488, 1240, 1176.

Industrial Applicability


- 5 According to the present invention, 2,3-dihydroazepine derivatives can be prepared in a few steps with safety by a process suitable for large-scale synthesis.

CLAIMS


1. A process for the preparation of a compound of the formula:



wherein each variable is as defined below, or a salt thereof, characterized in that a compound of the formula:



wherein X is a halogen atom; Y is an electron-withdrawing group; R⁶ and R⁷ are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R⁶ and R⁷ may form a ring, or a salt thereof, is allowed to react with a compound of the formula:




wherein R¹ is an optionally substituted hydrocarbon group,
 an optionally substituted acyl group, or an optionally
 substituted sulfonyl group; R², R³, R⁴, and R⁵ are independ-
 5 ently a hydrogen atom, a halogen atom, an optionally sub-
 stituted amino group, an optionally substituted hydroxyl
 group, an optionally substituted thiol group, an optionally
 substituted hydrocarbon group, or an optionally substituted
 heterocyclic group; or R¹ and R², R¹ and R⁴, R² and R³, R⁴
 10 and R⁵, or R² and R⁴ may form a ring, or a salt thereof.

2. The preparation process according to claim 1,
 wherein Y is an optionally substituted acyl group.


3. The preparation process according to claim 1,
 wherein R², R³, R⁴, and R⁵ are hydrogen atoms.

15 4. The preparation process according to claim 1,
 wherein R¹ is an optionally substituted hydrocarbon group.


5. A process for the preparation of a compound of
 the formula:



wherein each variable is as defined below, or a salt thereof, characterized in that a compound of the formula:




- 5 wherein X is a halogen atom; Y is an electron-withdrawing group; and ring A is an optionally substituted benzene ring, or a salt thereof, is allowed to react with a compound of the formula:



- 10 wherein R¹ is an optionally substituted hydrocarbon group, an optionally substituted acyl group, or an optionally substituted sulfonyl group; R², R³, R⁴, and R⁵ are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl


group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof.

- 5 6. The preparation process according to claim 1, characterized in that a compound of the formula:



wherein each variable is as defined in claim 1, or a salt thereof, is used, which is obtained by hydrolyzing a compound of the formula:


10




wherein each variable is as defined in claim 1, or a salt thereof.

7. The preparation process according to claim 6,

characterized in that the compound of the formula:




wherein each variable is as defined in claim 1, or a salt thereof, is subjected, without being isolated, to the reaction with the compound of the formula:



wherein each variable is as defined in claim 1, or a salt thereof.

8. A compound of the formula:



wherein Y is an electron-withdrawing group; R¹ is an optionally substituted hydrocarbon group, an optionally


substituted acyl group, or an optionally substituted sulfonyl group; R^2 , R^3 , R^4 , R^5 , R^6 , and R^7 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , R^2 and R^4 , or R^6 and R^7 may form a ring, or a salt thereof.

9. The compound according to claim 8, wherein Y is an optionally substituted acyl group.

10. The compound according to claim 8, wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms.

11. The compound according to claim 8, wherein R^1 is an optionally substituted hydrocarbon group.

12. A compound of the formula:



wherein Y is an electron-withdrawing group; ring A is an optionally substituted benzene ring; R^1 is an optionally substituted hydrocarbon group, an optionally substituted


acyl group, or an optionally substituted sulfonyl group; R^2 , R^3 , R^4 , and R^5 are independently a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; or R^1 and R^2 , R^1 and R^4 , R^2 and R^3 , R^4 and R^5 , or R^2 and R^4 may form a ring, or a salt thereof.

13. The compound according to claim 12, wherein Y is an optionally substituted acyl group.


14. The compound according to claim 12, wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms.

15. The compound according to claim 12, wherein R^1 is an optionally substituted hydrocarbon group.

16. A process for the preparation of a compound of the formula:



wherein R^8 is an optionally substituted hydrocarbon group and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein each variable is as defined in claim 1, or a salt thereof, which is obtained by the preparation process according to claim 1, is subjected to esterification.

17. The preparation process according to claim 16, wherein Y is an optionally substituted acyl group.

18. The preparation process according to claim 16, wherein R², R³, R⁴, and R⁵ are hydrogen atoms.


19. The preparation process according to claim 16, wherein R¹ is an optionally substituted hydrocarbon group.

20. A process for the preparation of a compound of the formula:




wherein R⁸ is an optionally substituted hydrocarbon group and the other variables are as defined below, or a salt

thereof, characterized in that a compound of the formula:




wherein each variable is as defined in claim 5, or a salt thereof, which is obtained by the preparation process according to claim 5, is subjected to esterification.

21. A process for the preparation of a compound of the formula:



wherein R⁹ is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined in claim 16, or a salt thereof, which is obtained by the preparation process according to claim 16, is subjected to ring-closing reaction.

22. The preparation process according to claim 21, wherein R^9 is a hydrogen atom.

23. The preparation process according to claim 21, wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms.


24. The process according to claim 21, wherein R^1 is an optionally substituted hydrocarbon group.

25. The preparation process according to claim 21, characterized in that a compound of the formula:




wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined in claim 16, or a salt thereof, which is obtained by the preparation process according to claim 16, is subjected, without being isolated, to ring-closing reaction.

26. A process for the preparation of a compound of the formula:



wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined below, or a salt thereof, characterized in that a compound of the formula:




wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined in claim 20, or a salt thereof, which is obtained by the preparation process according to claim 20, is subjected to ring-closing reaction.

27. The preparation process according to claim 26, wherein R^9 is a hydrogen atom.

28. The preparation process according to claim 26, wherein R^2 , R^3 , R^4 , and R^5 are hydrogen atoms.

29. The preparation process according to claim 26, wherein R^1 is an optionally substituted hydrocarbon group.


30. The preparation process according to claim 26, characterized in that a compound of the formula:




wherein Y^a is a group of formula $-COR^9$ wherein R^9 is a hydrogen atom or an optionally substituted hydrocarbon group, and the other variables are as defined in claim 20, or a salt thereof, which is obtained by the preparation process according to claim 20, is subjected, without being isolated, to ring-closing reaction.

ABSTRACT


As a process for preparing 2,3-dihydroazepine com-
pounds at low cost in a simple and easy manner, there is
5 provided a process for the preparation of compounds of the
formula:




or salts thereof, characterized in that compounds of the
formula:



10 or salts thereof are reacted with compounds of the formula:



or salts thereof to give compounds of the formula:



or salts thereof, which are then subjected to esterification and ring-closing reaction.

2025-03-03 10:00:00

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that:

私の住所、郵便の宛先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が求められている発明主題に関して、私は、最初、最先且つ唯一の発明者である（唯一の氏名が記載されている場合）か、或いは最初、最先且つ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROCESS FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE

COMPOUNDS

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☐ _____ の日に出願され、
この出願の米国出願番号またはPCT国際出願番号は、
_____ であり、且つ
_____ の日に補正された出願（該当する場合）

☒ was filed on September 5, 2000
as United States Application Number or
PCT International Application Number
PCT/JP00/06012 and was amended on
_____ (if applicable).

私は、上記の補正書によって補正された、特許請求範囲を含む上記明細書を検討し、且つ内容を理解していることをここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編規則1.56に定義されている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

私は、ここに、以下に記載した外国での特許出願または発明者証の出願、或いは米国以外の少なくとも一国を指定している米国法典第35編第365条(a)によるPCT国際出願について、同第119条(a)-(d)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出願日より前の出願日を有する外国での特許出願または発明者証の出願、或いはPCT国際出願については、いかなる出願も、下記の枠内をチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application for which priority is claimed.

Prior Foreign Application(s)

外国での先行出願

Priority Not Claimed

優先権主張なし

252334/1999

Japan

06/09/1999

(Number)
(番号)(Country)
(国名)(Day/Month/Year Filed)
(出願日/月/年)(Number)
(番号)(Country)
(国名)(Day/Month/Year Filed)
(出願日/月/年)

私は、ここに、下記のいかなる米国仮特許出願についても、その米国法典第35編第119条(a)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)(Filing Date)
(出願日)(Application No.)
(出願番号)(Filing Date)
(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国法典第35編第120条に基づく利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(c)に基づく利益を主張する。また、本出願の各特許請求の範囲の主題が、米国法典第35編第112条第1段に規定された態様で、先行する米国出願又はPCT国際出願に開示されていない場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、連邦規則法典第37編規則1.56に定義された特許性に関わる重要な情報について開示義務があることを承認する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可、係属中、放棄)(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可、係属中、放棄)

私は、ここに表明された私自身の知識に係わる陳述が真実であり、且つ情報と信ずることに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国法典第18編第1001条に基づき、罰金または拘禁、若しくはその両方により処罰され、またそのような故意による虚偽の陳述は、本出願またはそれに対して発行されるいかなる特許も、その有効性に問題が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Mark Chao, Reg. No. 37293; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Customer No. 23115

Send Correspondence to:

Mark Chao, PhD. JD.

Intellectual Property Department

Takeda Pharmaceuticals North America, Inc.

Suite 500, 475 Half Day Road

Lincolnshire, IL 60069 USA

直通電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, PhD. JD.

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, PhD. JD.

Voice: (847)383-3391 Fax: (847)383-3481

唯一または第一発明者氏名

Full name of sole or first inventor

Tomomi IKEMOTO

発明者の署名

日付

Inventor's signature

Date

Tomomi Ikemoto

Feb. 15, 2002

住所

Residence

Takarazuka-shi, Hyogo Japan JPX

国籍

Citizenship

Japan

Japan

郵便の宛先

Post Office Address

11-5, Yamamotomaruhashi 2-chome, Takarazuka-shi, Hyogo Japan

第二共同発明者がいる場合、その氏名

Full name of second joint inventor, if any

Tatsuya ITO

第二共同発明者の署名

日付

Second inventor's signature

Date

Tatsuya Ito

Feb. 15, 2002

住所

Residence

Kashiba-shi, Nara Japan JPX

国籍

Citizenship

Japan

Japan

郵便の宛先

Post Office Address

117.1-7 Asahigaoka-Kukakuseirichinai, 1214 Imaizumi Kashiba-shi, Nara Japan

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration (日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許商標庁との全ての業務を遂行するために、記名された発明者として、下記の弁護士及び/または弁理士を任命する。(氏名及び登録番号を記載すること)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Mark Chao, Reg. No. 37293; Elaine M. Ramesh, Reg. No. 43032

書類送付先

Send Correspondence to:

Mark Chao, PhD. JD.

Intellectual Property Department

Takeda Pharmaceuticals North America, Inc.

Suite 500, 475 Half Day Road

Lincolnshire, IL 60069 USA

直通電話連絡先: (氏名及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Mark Chao, PhD. JD.

Voice: (847)383-3391 Fax: (847)383-3481

Elaine M. Ramesh, PhD. JD.

Voice: (847)383-3391 Fax: (847)383-3481

第三共同発明者がいる場合、その氏名

Full name of third joint inventor, if any

Atsuko NISHIGUCHI

第三共同発明者の署名

日付

Third inventor's signature

Date

Atsuko Nishiguchi

Feb. 15, 2002

住所

Residence

Itami-shi, Hyogo Japan J P X

国籍

Citizenship

Japan

Japan

郵便の宛先

Post Office Address

151, Minamisuzuhara 3-chome, Itami-shi, Hyogo Japan

第四共同発明者がいる場合、その氏名

Full name of fourth joint inventor, if any

Kiminori TOMIMATSU

第四共同発明者の署名

日付

Fourth inventor's signature

Date

Kiminori Tomimatsu

Feb. 15, 2002

住所

Residence

Minoo-shi, Osaka Japan J P X

国籍

Citizenship

Japan

Japan

郵便の宛先

Post Office Address

12-12-A1002, Nishijuku 2-chome, Minoo-shi, Osaka Japan

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)